HIV/AIDS

Top Story

Harvoni leads to high real-world virologic response rates in HIV/HCV coinfection

Harvoni leads to high real-world virologic response rates in HIV/HCV coinfection
May 24, 2016

SAN DIEGO —  Harvoni, with or without ribavirin, yielded a 97% sustained virologic response rate in a real-world cohort of patients with genotype 1 hepatitis C virus and HIV, according to findings presented at Digestive Disease Week 2016.

Kris V. Kowdley, MD, of the Liver Care Network, Swedish Medical Center in Seattle, and colleagues, aimed to understand real-world outcomes across a heterogeneous population. The analysis included 140 patients who initiated therapy between October 2014 and March 2015. Patients were treated with Harvoni (ledipasvir/sofosbuvir, Gilead Sciences) for 8 (5%), 12 (75%) or 24 (20%) weeks.

In the JournalsPerspective

HIV patients less likely to receive treatment for many cancers

May 23, 2016
An analysis of more than 2 million U.S. cancer patients suggested that those with HIV are less likely to receive cancer treatment, regardless of insurance status or…
Video

VIDEO: Early initiation of ART has ‘important consequences’ for TB management

May 20, 2016
The evidence supporting early initiation of ART regardless of CD4 count has “several important consequences” related to managing tuberculosis in this…
In the Journals

Prompt ART improves HIV patient outcomes

May 20, 2016
A single-visit ART initiation and care program appeared to offer improved rates of viral suppression among African HIV patients, according to a recently published…
CME Video

Evolution of HIV Treatment: How to Start, How to Switch, How to Treat HIV/HCV Co-infection

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

Improvements in antiretroviral therapy (ART) continue to be made with the development of simplified, single-tablet…
More »
Video
Meeting News Coverage

VIDEO: Option B+ discussed at CROI 2016

February 27, 2016
More »
Featured
Zika Resource Center

Zika Resource Center

CME

The Patient with Diarrhea

No commercial support for this activity.

Intestinal infections with Clostridium difficile, a spore-forming gram-positive anaerobic bacillus, are among the most…
More »
Meeting News Coverage

Harvoni leads to high real-world virologic response rates in HIV/HCV coinfection

May 24, 2016
SAN DIEGO —  Harvoni, with or without ribavirin, yielded a 97% sustained virologic response rate in a real-world cohort of patients with…

In the JournalsPerspective

HIV patients less likely to receive treatment for many cancers

May 23, 2016
An analysis of more than 2 million U.S. cancer patients suggested that those with HIV are less likely to receive cancer treatment, regardless of…

Video

VIDEO: Early initiation of ART has ‘important consequences’ for TB management

May 20, 2016
The evidence supporting early initiation of ART regardless of CD4 count has “several important consequences” related to managing…

In the Journals

Prompt ART improves HIV patient outcomes

May 20, 2016
A single-visit ART initiation and care program appeared to offer improved rates of viral suppression among African HIV patients, according to a…

National data reveal prevalence of HIV among MSM on local level

May 18, 2016
HIV infection was confirmed to be hyperendemic among men who have sex with men in many parts of the United States, particularly in the South, an…

HIV Vaccine Awareness Day: Research continues for effective preventive, therapeutic vaccines

May 18, 2016
National HIV Vaccine Awareness Day is observed annually on May 18 to mark the progress made in developing an effective HIV vaccine, to acknowledge…

In the Journals

Researchers explore new HIV vaccine target

May 17, 2016
A research team led by the NIH discovered a vulnerable site on HIV that may be used as a target for future vaccines and identified a broadly…

High-dose HBV vaccine improves HIV patients’ long-term immune response

Infectious Disease News, May 2016
Recent findings show that HIV patients immunized with high-dose recombinant hepatitis B vaccine demonstrated improved immune responses at 42 months…

PrEP uptake poised to grow as physicians gain insight, stigmas fade

Infectious Disease News, May 2016
Pre-exposure prophylaxis, or PrEP, has been approved for HIV prevention in the United States since 2012, and guidelines for its use have been in…

Video

VIDEO: Alan Taege, MD, reviews recently approved agents for HIV

May 12, 2016
The agents approved for HIV in recent years can be separated “into several categories,” according to Alan Taege, MD, of the…

More Headlines »